Faron Pharma Share News (FARN)

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

UK earnings, trading statements calendar - next 7 days

UK shareholder meetings calendar - next 7 days

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

EARNINGS UPDATES: Everyman revenue doubles; Aeorema in interim profit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: